Endless Biotech Welcomes Tim Lozott as CFO, Setting Course for Nasdaq Listing

Tulsa, OK – [Date] – Endless Biotech proudly announces the appointment of Tim Lozott as its Chief Financial Officer (CFO). Mr. Lozott joins Endless Biotech with a wealth of experience and a proven track record in the cannabis industry, where he has served as a fully vertical operator. His strategic vision and financial acumen will play a pivotal role in positioning Endless Biotech as a global leader in pharmaceutical-grade tissue cultures and clone genetics for cannabis cultivators worldwide. Mr. Lozott will oversee all finance and accounting functions, spearheading efforts to drive financial growth and operational excellence.

Mr. Lozott’s mandate includes implementing a "Scale, Grow or Die" strategy and preparing for an anticipated exit strategy onto the Nasdaq Stock Exchange by the end of 2028. His expertise in mergers and acquisitions, along with land and property acquisitions, will support Endless Biotech's ambitious growth and expansion plans. Notably, Mr. Lozott's career highlights include managing and co-managing REITs valued at over $2 billion, demonstrating his proficiency in asset management and strategic investment.

Chief Executive Officer Travis Dahm expressed confidence in Mr. Lozott’s appointment, stating, "Mr. Lozott's leadership will be instrumental as we navigate through our planned growth phases, including future mergers and acquisitions and strategic property acquisitions. His experience in orchestrating a $100 million exit of Acres Cannabis NV to Curaleaf positions him uniquely to guide Endless Biotech towards achieving its strategic goals."

Mr. Lozott shared his vision for Endless Biotech's future, stating, "As CFO, my primary objective is to lead Endless Biotech towards becoming a fully listed Nasdaq company by the end of 2028. Over the next three years, we will leverage Regulation A stock offerings to raise capital for our planned expansions and strategic acquisitions within the vertically integrated cannabis sector. These efforts will bolster our assets and revenues, paving the way for a successful listing on the Nasdaq stock exchange."

With Mr. Lozott’s appointment, Endless Biotech is poised to capitalize on its strengths, drive innovation, and strengthen its position as a leader in the global cannabis industry.

About Endless Biotech

Endless Biotech specializes in pharmaceutical-grade tissue cultures, clone genetics, genetic preservation, disease cleanup, and virus testing. With a mission to provide disease- and pest-free cannabis plants, Endless combines pioneering science and cutting-edge technology to serve grow operations globally. The company’s team includes world-renowned scientists and researchers dedicated to advancing the cannabis industry.

Forward Looking Statements

This media advisory contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans", "expects" or "proposed", "is expected", "intends", "anticipates", or "believes", or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward-looking statements and information concerning the launch of Cross Marketing & Strategic Partners initiatives. Such forward-looking statements and information reflect management's current beliefs and are based on assumptions made by and information currently available to the company with respect to the matter described in this new release. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information about these assumptions and risks and uncertainties is contained under "Risk Factors and Uncertainties" in the Company's latest annual information and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Securities & Exchange Committee (SEC) has not reviewed, approved or disapproved the content of this news release.